Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
Authors:
- Daniel Richard GomezDGDaniel Richard Gomez
- Lauren Averett ByersLBLauren Averett Byers
- Monique NilssonMNMonique Nilsson
- Lixia DiaoLDLixia Diao
- Jing WangJWJing Wang
- Lerong LiLLLerong Li
- Pan TongPTPan Tong
- Mia HofstadMHMia Hofstad
- Ignacio WistubaIWIgnacio Wistuba
- Neda KalhorNKNeda Kalhor
- Stephen SwisherSSStephen Swisher
Open Access
- 30 January 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (18) , 14268-14284
Abstract
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerKeywords
This publication has 63 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceClinical Cancer Research, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapyCell Death & Differentiation, 2011
- Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung CancerClinical Cancer Research, 2011
- Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with RecurrenceJournal of Thoracic Oncology, 2010
- The Emerging Role of the RAB25 Small GTPase in CancerTraffic, 2009
- EGFR Signals to mTOR Through PKC and Independently of Akt in GliomaScience Signaling, 2009
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- The RAB25 small GTPase determines aggressiveness of ovarian and breast cancersNature Medicine, 2004